An economic development model based on attracting tax revenue at the expense of other countries can only last as long as they tolerate it, economist Gabriel Zucman warns in an extensive interview.
Multinationals led by pharmaceutical manufacturers have long used intangible assets and transfer pricing to shift profits to Ireland. Could the same moves work in reverse to reduce exposure to tariffs?
Hearing the case in the commercial court, Mr Justice Sanfey told Keith O'Brien, the payroll manager accused of leaking trade secrets to Rippling's rival, Deel, that he was in “a very serious situation”.
In an affidavit opened in the High Court in Dublin, Rippling has alleged that Keith O'Brien disclosed "trade secrets" to rival HR firm Deel.
The agreement is the latest sign of efforts by European countries to tax profits booked by multinationals in Ireland.
Tech and pharma firms woke up from the presidential inauguration night with no tariffs or tax moves affecting their Irish structures. The threats are real, however.
Deadlines are looming on key rules deciding how American multinationals’ profits are taxed in Ireland. Trump and his supporters in Congress have yet to decide how much they will let away this time.
Labour and the incoming Irish government will have to place a significant emphasis on US relations in the new year with both facing threats from a protectionist Trump regime.
Behind a veil of prudence, Government projections continue to forecast rapid growth in corporation tax revenue. For another week, they appear not to be wrong.
The Dutch giant is selling its stake in multiple public infrastructure projects, but not in the National Children’s Hospital. Some of its motorway co-investors are making moves too.
© 2025 Currency Media Limited
